CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-04). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 2146 · Search date 2026-08-04 · Methodology v0.6

Drinking about 1.4 L of coffee daily,
does it really help with Prevention of incident invasive colon cancer?

30-Second Summary
D
Evidence Grade D · 39 · Safety caution
A large prospective analysis extending to about 1.4 L/day found no colon-cancer prevention association
About 1.4 L daily can deliver substantial caffeine depending on the product and may cause insomnia, palpitations, anxiety, or gastrointestinal symptoms.
What the
research shows
The grade is D. An individual-participant pooled analysis of 13 prospective cohorts included 731,441 people and 5,604 invasive colon cancers. Compared with non-drinkers, intake above 1,400 g/day had a relative risk of 1.07 (95% CI 0.89 to 1.30). This large observational result did not support prevention, but it was not randomized and the interval still allowed some benefit, giving D with 39 points.
What the
ads claim
The presence of caffeine and polyphenols in coffee does not establish cancer prevention. Even the roughly 1.4-L group did not have less colon cancer than non-drinkers in this analysis.
*

Useful facts when choosing a product

  • The highest category exceeded 1,400 g/day, described as about six 8-oz cups or 1.4 L.
  • Brewing method and study-specific caffeine content were not measured or reported; decaffeinated coffee was not consistently separated.
  • The FDA's general range for 12 fl oz of regular brewed non-specialty coffee is 113 to 247 mg caffeine; this was not a measurement of cohort beverages.
Gap Measurement · Verdict 2146 · D 39
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Zhang pooled individual data from 13 prospective cohorts, 11 of which supplied coffee data. Among 731,441 people, 5,604 invasive colon cancers occurred. More than 1,400 g/day versus none gave 1.07 (0.89 to 1.30), P for trend .68; per 250 g, estimates were 0.99 (0.97 to 1.02) overall, 0.99 (0.96 to 1.02) proximal, and 0.99 (0.96 to 1.03) distal. Rectal cancer was not an endpoint. Cohort estimates straddled 1, while between-study heterogeneity for the highest category was not significant, P>.20.

02

Why this is classified as D (39)

A large prospective pooled analysis was null, but nonrandomized design and an interval allowing some benefit give D with 39 points.

Counterpoint. This verdict does not address recurrence or survival after diagnosis, other cancers, or coffee extracts.

Rejudgment record. Cross-check applied — A pooled individual-participant analysis of 13 prospective cohorts was null for incident invasive colon cancer while its interval still allowed some benefit

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE0Null
PrecisionC0The confidence interval leaves room for benefit

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Prevention of incident invasive colon cancerDThe highest-intake RR was 1.07 (0.89 to 1.30), showing no preventive association.
Prevention of proximal or distal colon cancerDThe pivotal pooled analysis found no material difference by tumor site.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Pooled analysis of 13 prospective cohorts5,604NIH CA55075 and nonprofit research supportIncident invasive colon cancer>1,400 g/day versus none: RR 1.07 (95% CI 0.89 to 1.30), P trend=.68Decisive large prospective evidence
Study 2Dose-response meta-analysis of prospective cohorts22,629Funding could not be confirmed in the accessible recordIncident colorectal, colon, and rectal cancerFour cups/day was associated with about 7% lower colon-cancer risk, while rectal cancer was not significantIndirect, non-comparable discordance
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-08-04).

Zhang X, et al. Risk of Colon Cancer and Coffee, Tea, and Sugar-Sweetened Soft Drink Intake: Pooled Analysis of Prospective Cohort Studies. J Natl Cancer Inst. 2010;102:771-783. PMID: 20453203. DOI: 10.1093/jnci/djq107.
checked
Gan Y, et al. Association of coffee consumption with risk of colorectal cancer: a meta-analysis of prospective cohort studies. Oncotarget. 2017;8:18699-18711. PMID: 27078843. DOI: 10.18632/oncotarget.8627.
checked
U.S. Food and Drug Administration. Spilling the Beans: How Much Caffeine is Too Much?
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-04 · Corrections: none

Cite this verdict

Drinking about 1.4 L of coffee daily x colon-cancer prevention Evidence Grade D card
[Chamgap] Drinking about 1.4 L of coffee daily x colon-cancer prevention — Evidence Grade D·39. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/drinking-coffee-colon-cancer-prevention/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.